ImmuCell Announces Results for Third Quarter of 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ImmuCell Announces Results for Third Quarter of 2015

PORTLAND, ME --(Marketwired - November 12, 2015) - ImmuCell Corporation ( NASDAQ : ICCC ), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for its third quarter ended September 30, 2015.

2015 Third Quarter Financial Overview:

  • Total sales increased 40% to $2.47 million compared to third quarter 2014;
  • 13 th consecutive quarter of positive sales growth and 19 th quarter of positive sales growth out of the last 20 quarters (in comparison to the same quarters of the prior years);
  • Total sales increased 40% to $7.53 million compared to first nine months of 2014;
  • First Defense ® sales increased 43%, or $2.08 million, compared to first nine months of 2014;
  • Net income of $351,000, or $0.11 per diluted share, during third quarter 2015 compared to net income of $10,000, or $0.00 per diluted share, during third quarter 2014;
  • Net income of $924,000, or $0.29 per diluted share, during first nine months of 2015 in contrast to net (loss) of ($298,000), or ($0.10) per share, during first nine months of 2014;
  • Net cash provided by operating activities of $2.07 million during first nine months of 2015 in comparison to $50,000 during first nine months of 2014;
  • Net cash provided by operating activities of $2.32 million during the twelve-month period ended September 30, 2015 in comparison to $134,000 during the twelve-month period ended September 30, 2014; and
  • Cash, cash equivalents, short-term investments and long-term investments of $6.68 million as of September 30, 2015.

Other Milestones/Developments:

  • During the third quarter of 2015, the Company closed on a $2.5 million secured debt financing;
  • During the fourth quarter of 2015, the Company extended its contract with Plas-Pak, Inc. covering the supply of its proprietary syringe for Mast Out ® through December 31, 2020;
  • Investment to increase liquid processing production capacity for First Defense ® by 50% completed during fourth quarter 2015; and
  • Investment to increase freeze-drying production capacity for First Defense ® by 100% proceeding on schedule and expected to be completed before the end of first quarter 2016.

Other Financial Results for Third Quarter of 2015:

ImmuCell's product sales are normally seasonal, with higher sales expected during the first quarter. Total product sales during the three-month period ended September 30, 2015 increased by 40%, or $702,000, to $2,472,000 from $1,770,000 during the same period in 2014. Total product sales during the nine-month period ended September 30, 2015 increased by 40%, or $2,143,000, to $7,534,000 from $5,392,000 during the same period in 2014. Total product sales during the trailing twelve months ended September 30, 2015 increased by 40%, or $2,789,000, to $9,740,000 from $6,951,000 during the same period in 2014. The Company held a backlog of orders for First Defense ® aggregating approximately $1,554,000 as of September 30, 2015.

Sales of First Defense ® and related product line extensions increased by 43% during the first nine months of 2015, in comparison to the same period in 2014. ImmuCell's sales and marketing team is doing an effective job introducing First Defense ® to new customers and communicating how the product provides Immediate Immunity ™ to newborn calves, generating a dependable return on investment to dairy and beef producers. Sales also benefited from a strong beef price and from the temporarily interrupted supply to the market of a competitive product. This new level of sales demand has exceeded the Company's current production capacity and available inventory, resulting in a backlog of First Defense ® orders.

Product development expenses decreased by 16%, or $59,000, to $302,000 during the third quarter of 2015, as compared to $361,000 during the same period in 2014. Product development expenses aggregated 12% and 20% of product sales during the third quarters of 2015 and 2014, respectively. Product development expenses decreased by 47%, or $812,000, to $904,000 during the first nine months of 2015 as compared to $1,716,000 during the same period in 2014. Product development expenses aggregated 12% and 32% of product sales during the first nine months of 2015 and 2014, respectively. The higher expenses during the 2014 periods were largely the result of expenses incurred in connection with the Company's small-scale Nisin production plant investment.

Income before income taxes was approximately $612,000 during the third quarter of 2015 in comparison to income before income taxes of $30,000 during the same period in 2014. Net income was $351,000, or $0.11 per diluted share, during the third quarter of 2015 in comparison to net income of $10,000, or $0.00 per diluted share, during the same period in 2014.

Income before income taxes was approximately $1,634,000 during the first nine months of 2015 in contrast to a (loss) before income taxes of ($444,000) during the same period in 2014. Net income was $924,000, or $0.29 per diluted share, during the first nine months of 2015 in contrast to net (loss) of ($298,000), or ($0.10) per share, during the same period in 2014.

Management's Discussion: Michael F. Brigham, President and CEO, commented, "As we continue to benefit from strong increases in First Defense ® product sales, we are completing the investments necessary to increase our production capacity to fill the current backlog of orders, and we are taking the initial steps towards constructing our own facility for the commercial-scale production of Nisin for Mast Out ® ."

Mr. Brigham continued, "Our registration statement on Form S-3 filed with the SEC for the potential issuance of up to $10 million in equity (subject to certain limitations) became effective on November 10, 2015. While we monitor market conditions going forward, we are also exploring additional debt financing to secure the capital necessary to bring Mast Out ® to market, subject to FDA approval."

"We continue to execute on the two core components of our business strategy," Mr. Brigham added. "First, we are expanding the market penetration of First Defense ® , our best-in-class treatment for calf scours. The addition of a bovine rotavirus disease claim to our existing claims against E. coli and coronavirus infections could allow us to bring the first passive antibody product with this breadth of disease claims to market in 2016. Second, we are advancing the development of Mast Out ® , our novel treatment for subclinical mastitis in lactating dairy cows. Our ground-breaking product innovation is unlike all other mastitis treatments on the market today that are all sold subject to a milk discard period. Our goal is to revolutionize the way mastitis is treated by making earlier treatment of subclinical infections economically feasible by not requiring a milk discard or meat withhold during, or for a period of time after, treatment. No other product presently on the market can offer this value proposition."

Conference Call Interested parties can access the conference call by dialing (866) 652-5200 or (412) 317-6060 at 4:30 PM EST today. A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation #10075804. A live Internet webcast will be available at https://www.webcaster4.com/Webcast/Page/1214/11559 and a webcast replay will be available for 90 days at the same address.

About ImmuCell ImmuCell Corporation's ( NASDAQ : ICCC ) purpose is to create scientifically-proven and practical products that improve animal health and productivity in the dairy and beef industries. ImmuCell has developed products that provide significant, immediate immunity to newborn dairy and beef livestock. The Company has also developed products that address mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at: ( http://www.immucell.com ).

   
Unaudited Condensed Statements of Operations  
           
    For the Three-Month Periods Ended  September 30,   For the Nine-Month  Periods Ended  September 30,  
(In thousands, except per share amounts)   2015   2014   2015   2014  
                   
Product sales   $2,472   $1,770   $7,534   $5,392  
Cost of goods sold   860   692   2,941   2,285  
  Gross margin   1,612   1,078   4,593   3,107  
                   
Sales, marketing and administrative expenses   683   676   2,028   1,796  
Product development expenses   302   361   904   1,716  
    Operating expenses   985   1,037   2,932   3,512  
                   
NET OPERATING INCOME (LOSS)   627   41   1,661   (405 )
                   
Other expenses, net   15   11   27   39  
                   
INCOME (LOSS) BEFORE INCOME TAXES   612   30   1,634   (444 )
                   
Income tax expense (benefit)   261   20   710   (146 )
                   
NET INCOME (LOSS)   $351   $10   $924   ($298 )
                   
Weighted average common shares outstanding:                  
    Basic   3,052   3,027   3,038   3,027  
    Diluted   3,188   3,106   3,163   3,027  
                       
NET INCOME (LOSS) PER SHARE:                  
    Basic   $0.12   $0.00   $0.30   ($0.10 )
    Diluted   $0.11   $0.00   $0.29   ($0.10 )
                   
                   
 
Unaudited Selected Balance Sheet Data
        (Audited)
    As of September 30, 2015   As of  December 31, 2014
(In thousands)        
Cash, cash equivalents, short-term and long-term investments   $6,676   $3,835
Net working capital   7,507   4,460
Total assets   14,223   11,052
Stockholders' equity   $10,298   $9,258
         

Safe Harbor Statement: This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: projections of future financial performance; the scope and timing of future product development work and commercialization of our products; future costs of product development efforts; the estimated prevalence rate of subclinical mastitis; future market share of and revenue generated by products still in development; future sources of financial support for our product development, manufacturing and marketing efforts; the future adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the amount and timing of future investments in facility modifications and production equipment; the future adequacy of our working capital and the availability of third party financing; timing and future costs of a facility to produce the Drug Substance (active pharmaceutical ingredient) for Mast Out ® ; the timing and outcome of pending or anticipated applications for future regulatory approvals; future regulatory requirements relating to our products; future expense ratios and margins; future compliance with bank debt covenants; future realization of deferred tax assets; costs associated with sustaining compliance with cGMP regulations in our current operations and attaining such compliance for the facility to produce the Drug Substance for Mast Out ® ; factors that may affect the dairy and beef industries and future demand for our products; the cost-effectiveness of additional sales and marketing expenditures and resources; the accuracy of our understanding of our distributors' ordering patterns; anticipated changes in our manufacturing capabilities and efficiencies; anticipated competitive and market conditions; and any other statements that are not historical facts. Forward-looking statements can be identified by the use of words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts" and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, alignment between our manufacturing resources and product demand, the uncertainties associated with product development and Drug Substance manufacturing, our potential reliance upon third parties for financial support, products and services, changes in laws and regulations, decision making by regulatory authorities, possible dilutive impacts on existing stockholders from any equity financing transactions in which we may engage, currency fluctuations and other risks detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements are based on our current expectations, but actual results may differ materially due to various factors, including the risk factors summarized below and uncertainties otherwise referred to in this press release.

Contact: Michael F. Brigham President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 iccc@lythampartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 181

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 100

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 48

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Review Lawsuit Against Cepton, Inc. (CPTN)

Updated Category News Views 203

Class Action Against Cepton, Inc. Unveiled Recent developments have raised significant concerns for investors of Cepton, Inc. (NASDAQ: CPTN) following revelations of a class action lawsuit. Leading national plaintiffs' law firm Berger Montague has stepped in to help those impacted. The lawsuit focuses on investors who bought or sold Cepton shares during a specified...

Continue Reading
Exploring Uber Technologies: A Strategic Trade Perspective

Updated Category News Views 172

Uber Technologies Inc.'s Current Market Position Recently, ride-sharing giant Uber Technologies, Inc. (NYSE: UBER) experienced a notable increase in its market value. This uplift followed an innovative announcement regarding the capability for riders to book an Avride robotaxi, showcasing the evolution of autonomous mobility solutions. In the past five trading days, UBER...

Continue Reading
Celebrating Diversity: Winners of the Art Limitless Contest

Updated Category News Views 168

Celebrating the Art Limitless Competition Winners In the heart of artistic innovation, BE OPEN has unveiled the winners of the Art Limitless competition, an initiative celebrating inclusivity and diversity in the arts. This remarkable program strives to empower artists with disabilities, showcasing their work while inspiring broader societal awareness. What is Art...

Continue Reading
Certuity Welcomes Constantine Hatzivassiliou as New Partner

Updated Category News Views 246

Certuity Welcomes Constantine Hatzivassiliou as New Partner Certuity, a leading multi-family office dedicated to serving high-net-worth individuals and families, is thrilled to announce the promotion of Managing Director Constantine Hatzivassiliou to Partner. This significant advancement not only reflects Hatzivassiliou's commitment to the firm but also the invaluable...

Continue Reading
Sila Realty Trust, Inc.'s Key Updates on Q3 2024 Earnings

Updated Category News Views 124

Sila Realty Trust, Inc. Announces Upcoming Q3 Earnings Release Sila Realty Trust, Inc. (NYSE: SILA) recently made an announcement regarding its anticipated financial results for the third quarter of 2024. The company will release these earnings on a Tuesday morning, just before the market opens. This timely communication reflects Sila's commitment to transparency and...

Continue Reading